Elevated intraocular pressure (IOP) is an important risk factor for glaucoma. Mechanisms involved in its homeostasis are not well understood, but associations between metabolic factors and IOP have been reported. To investigate the relationship between levels of circulating metabolites and IOP, we performed a metabolome-wide association using a machine learning algorithm, and then employing Mendelian Randomization models to further explore the strength and directionality of effect of the metabolites on IOP. We show that O-methylascorbate, a circulating Vitamin C metabolite, has a significant IOP-lowering effect, consistent with previous knowledge of the anti-hypertensive and anti-oxidative role of ascorbate compounds. These results enhance understanding of IOP control and may potentially benefit future IOP treatment and reduce vision loss from glaucoma.
Ascorbic acid metabolites are involved in intraocular pressure control in the general population / P. Hysi, A. Khawaja, C. Menni, B. Tamraz, N. Wareha, K. Khaw, P. Foster, L. Benet, T. Spector, C. Hammond. - In: REDOX BIOLOGY. - ISSN 2213-2317. - 20:(2019), pp. 349-353. [10.1016/j.redox.2018.10.004]
Ascorbic acid metabolites are involved in intraocular pressure control in the general population
C. Menni;
2019
Abstract
Elevated intraocular pressure (IOP) is an important risk factor for glaucoma. Mechanisms involved in its homeostasis are not well understood, but associations between metabolic factors and IOP have been reported. To investigate the relationship between levels of circulating metabolites and IOP, we performed a metabolome-wide association using a machine learning algorithm, and then employing Mendelian Randomization models to further explore the strength and directionality of effect of the metabolites on IOP. We show that O-methylascorbate, a circulating Vitamin C metabolite, has a significant IOP-lowering effect, consistent with previous knowledge of the anti-hypertensive and anti-oxidative role of ascorbate compounds. These results enhance understanding of IOP control and may potentially benefit future IOP treatment and reduce vision loss from glaucoma.| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2213231718306839-main.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
468.7 kB
Formato
Adobe PDF
|
468.7 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.




